Skip to content

Press Releases and Events

Press Releases

Filter Releases
 
Press Releases and Events
Date Title and Summary View
Nov 9, 2016
NEW YORK, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the quarter ended September 30, 2016, and provided a corporate update. ...
Nov 2, 2016
NEW YORK, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, No...
Oct 31, 2016
NEW YORK, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) today announced presentation (in oral and poster forms) of results from its clinical development program in schizophrenia that has replicated the efficacy of ITI-007 60 mg in two studies and found it to be safe and well tolerated in three large, well-con...
Sep 28, 2016
NEW YORK, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) today announced top-line results from the second Phase 3 clinical trial (Study ‘302) of ITI-007, an oral, first-in-class investigational medicine for the treatment of schizophrenia. In this trial, neither dose of ITI-007 separated ...
Aug 4, 2016
NEW YORK, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the quarter ended June 30, 2016, and provided a corporate update. ...
Jul 25, 2016
NEW YORK, July 25, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, August 4, 2016...
Jul 6, 2016
NEW YORK, July 06, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at Cantor Fitzge...
Jun 30, 2016
NEW YORK, June 30, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced completion of enrollment in the second Phase 3 clinical trial (ITI-007-302) of the Company's lead product candidate I...
Jun 28, 2016
NEW YORK, June 28, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that, following communication with the U.S. Food and Drug Administration (FDA), the Company has initiated Phase 3 dev...
Jun 15, 2016
NEW YORK, June 15, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and ...
May 31, 2016
NEW YORK, May 31, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Jefferies 2016 Healthcare ...
May 26, 2016
NEW YORK, May 26, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that data related to ITI-007, the Company's lead product candidate, will be featured in a poster at the American Society ...
May 18, 2016
NEW YORK, May 18, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it presented posters related to ITI-007, the Company's lead product candidate, at the 2016 Society of Biological Psychiatry...
May 10, 2016
NEW YORK, May 10, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that data related to ITI-007, the Company's lead product candidate, will be featured in several poster pres...
May 4, 2016
NEW YORK, May 04, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Bank of America Merrill ...
= add release to Briefcase

Upcoming Events

Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.